{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T10:55:54Z","timestamp":1772794554923,"version":"3.50.1"},"reference-count":18,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"vor","delay-in-days":61,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Although randomized studies are designed to assess overall survival (OS) benefit, the conduct of regulatory studies in patients with orphan diseases can be timely and costly without offering the same commercial return on the investment. The peripheral T-cell lymphomas (PTCL) represent a rare group of heterogeneous lymphoid malignancies with very poor prognosis. PROPEL was a pivotal phase II study that led to the accelerated approval of pralatrexate for patients with relapsed or refractory PTCL.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>An international database of 859 patients was assembled from four institutions with an interest in PTCL, of which 386 were considered eligible for matching against the PROPEL criteria. Using a rigorous propensity score matching algorithm, a unique 1:1 case match of 80 patients was performed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The analysis demonstrated an OS benefit for the PROPEL population with a median OS of 4.07 and 15.24\u2009months (hazard ratio = 0.432, 95% confidence interval = 0.298 to 0.626), respectively, for the control and PROPEL populations. Highly statistically significant improvements in OS were noted for the PROPEL population about the subtype of PTCL (save anaplastic large cell lymphoma) and all age groups, including the elderly (&gt;65\u2009years of age). For patients on PROPEL, there was a statistically significant prolongation in progression free survival compared with the line of prior therapy, including those with refractory disease.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In the context of this case-match-control study, patients treated on PROPEL experienced an OS advantage compared with an international database of historical controls. This information can help inform critical decision-making regarding clinical studies in PTCL.<\/jats:p><\/jats:sec>","DOI":"10.1093\/jncics\/pky038","type":"journal-article","created":{"date-parts":[[2018,7,24]],"date-time":"2018-07-24T21:26:02Z","timestamp":1532467562000},"source":"Crossref","is-referenced-by-count":14,"title":["Strategy for Assessing New Drug Value in Orphan Diseases: An International Case Match Control Analysis of the PROPEL Study"],"prefix":"10.1093","volume":"2","author":[{"given":"Owen A","family":"O\u2019Connor","sequence":"first","affiliation":[{"name":"Department of Medicine, Center for Lymphoid Malignancies, Columbia University Medical Center, College of Physicians and Surgeons, New York, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrica","family":"Marchi","sequence":"additional","affiliation":[{"name":"Department of Medicine, Center for Lymphoid Malignancies, Columbia University Medical Center, College of Physicians and Surgeons, New York, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weining","family":"Volinn","sequence":"additional","affiliation":[{"name":"LLX Solutions, Waltham, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"Shi","sequence":"additional","affiliation":[{"name":"LLX Solutions, Waltham, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Mehrling","sequence":"additional","affiliation":[{"name":"LLX Solutions, Waltham, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Won Seog","family":"Kim","sequence":"additional","affiliation":[{"name":"Samsung Medical Center, Seoul, South Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2018,12,1]]},"reference":[{"issue":"20","key":"2019070511525076500_pky038-B1","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"2","key":"2019070511525076500_pky038-B2","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.hoc.2016.11.002","article-title":"Novel agents in the treatment of relapsed or refractory peripheral T-cell lymphoma","volume":"31","author":"Marchi","year":"2017","journal-title":"Hematol Oncol Clin North Am"},{"issue":"12","key":"2019070511525076500_pky038-B3","first-page":"837","article-title":"Emerging therapies in relapsed and refractory peripheral T-cell lymphoma","volume":"13","author":"Bachow","year":"2015","journal-title":"Clin Adv Hematol Oncol"},{"issue":"25","key":"2019070511525076500_pky038-B4","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J Clin Oncol."},{"issue":"19","key":"2019070511525076500_pky038-B5","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1182\/blood-2013-11-536359","article-title":"Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma","volume":"123","author":"Iqbal","year":"2014","journal-title":"Blood"},{"issue":"1","key":"2019070511525076500_pky038-B6","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1056\/NEJMc1111708","article-title":"TET2 and DNMT3A mutations in human T-cell lymphoma","volume":"366","author":"Couronne","year":"2012","journal-title":"N Engl J Med"},{"issue":"19","key":"2019070511525076500_pky038-B7","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1182\/blood-2013-12-544809","article-title":"GATA-3 expression identifies a high-risk subset of PTCL, NOS with distinct molecular and clinical features","volume":"123","author":"Wang","year":"2014","journal-title":"Blood"},{"issue":"9","key":"2019070511525076500_pky038-B8","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1200\/JCO.2010.29.9024","article-title":"Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study","volume":"29","author":"O'Connor","year":"2011","journal-title":"J Clin Oncol."},{"issue":"26","key":"2019070511525076500_pky038-B9","doi-asserted-by":"crossref","first-page":"4357","DOI":"10.1200\/JCO.2008.20.8470","article-title":"Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies","volume":"27","author":"O'Connor","year":"2009","journal-title":"J Clin Oncol."},{"issue":"33","key":"2019070511525076500_pky038-B10","doi-asserted-by":"crossref","first-page":"4877","DOI":"10.1200\/JCO.2009.26.5983","article-title":"Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers","volume":"28","author":"Von Hoff","year":"2010","journal-title":"J Clin Oncol."},{"issue":"3","key":"2019070511525076500_pky038-B11","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies","volume":"46","author":"Austin","year":"2011","journal-title":"Multivariate Behav Res."},{"issue":"19","key":"2019070511525076500_pky038-B12","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1002\/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B","article-title":"Tutorial in biostatistics: propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group","volume":"17","author":"D\u2019Agostino","year":"1998","journal-title":"Stat. Med."},{"issue":"1","key":"2019070511525076500_pky038-B13","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1080\/00031305.1985.10479383","article-title":"Constructing a control group using multivariate matched sampling methods that incorporate the propensity score","volume":"39","author":"Rosenbaum","year":"1985","journal-title":"Am Stat"},{"key":"2019070511525076500_pky038-B14","author":"Parsons","year":"2004"},{"key":"2019070511525076500_pky038-B15","doi-asserted-by":"crossref","first-page":"7","DOI":"10.7150\/jca.3.7","article-title":"Progression-free survival decreases with each subsequent therapy in patients presenting for phase I clinical trials","volume":"3","author":"Bailey","year":"2012","journal-title":"J Cancer"},{"issue":"15","key":"2019070511525076500_pky038-B16","doi-asserted-by":"crossref","first-page":"e451","DOI":"10.1200\/JCO.2010.34.0380","article-title":"Progression-free survival ratio as end point for phase II trials in advanced solid tumors","volume":"29","author":"Buyse","year":"2011","journal-title":"J Clin Oncol"},{"issue":"16","key":"2019070511525076500_pky038-B17","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1200\/JCO.2012.44.7524","article-title":"Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors","volume":"31","author":"Mak","year":"2013","journal-title":"J Clin Oncol"},{"issue":"12","key":"2019070511525076500_pky038-B18","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1080\/10428194.2017.1300888","article-title":"Outcome of peripheral T-cell lymphoma in first complete remission: a Danish-Swedish population-based study","volume":"58","author":"Cederleuf","year":"2017","journal-title":"Leuk Lymphoma."}],"container-title":["JNCI Cancer Spectrum"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jncics\/article-pdf\/2\/4\/pky038\/28907902\/pky038.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T15:53:44Z","timestamp":1720454024000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jncics\/article\/doi\/10.1093\/jncics\/pky038\/5224845"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,1]]},"references-count":18,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2018,12,1]]},"published-print":{"date-parts":[[2018,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jncics\/pky038","relation":{},"ISSN":["2515-5091"],"issn-type":[{"value":"2515-5091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,10]]},"published":{"date-parts":[[2018,10,1]]},"article-number":"pky038"}}